# A Study of AK112 in Advanced Malignant Tumors

> **NCT05214482** · PHASE1,PHASE2 · COMPLETED · sponsor: **Akeso** · enrollment: 154 (actual)

## Conditions studied

- Advanced Malignant Tumors

## Interventions

- **DRUG:** AK112
- **DRUG:** AK117
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT05214482
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-22
- **Primary completion:** 2025-11-20
- **Final completion:** 2025-12-31
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05214482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05214482, "A Study of AK112 in Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05214482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*